The prescription drug form of PT-141 is genuinely FDA-approved, which sets it apart from most of this list. The approval is also narrower, and more specific to one condition and one population, than the general framing it usually gets online.
What PT-141 is
PT-141, known by its generic name bremelanotide, is a melanocortin receptor agonist that acts in the brain, unlike older treatments for sexual dysfunction that work on hormones or blood vessels directly. It's marketed as a prescription pharmaceutical under the brand name Vyleesi.
What's actually been studied
- Regulatory approval trials. The FDA approved bremelanotide in June 2019 as Vyleesi, based on two Phase 3 randomized controlled trials enrolling over a thousand patients combined. It was the second FDA-approved pharmacological treatment for hypoactive sexual desire disorder (HSDD), after flibanserin (Addyi) in 2015, and the first approved for on-demand rather than daily use.
- What the approval covers. The approved indication is specifically acquired, generalized hypoactive sexual desire disorder in premenopausal women, a defined clinical diagnosis, not sexual dysfunction in general. Trials reported improvements in measures of sexual desire and desire-related distress in the treated group compared with placebo.
- Use outside the approved population. PT-141 has also been investigated for sexual desire and erectile function in men, a population and use case outside its current FDA approval.
Where the evidence is thin
The approval trials are real, human, randomized, and reasonably large by this category's standards. The gap that matters is the same one that shows up across the FDA-approved prescription drugs on this site: the approval covers a specific diagnosed condition, a specific population (premenopausal women with HSDD), and a specific, physician-dispensed pharmaceutical product. Research-chemical PT-141 sold by peptide vendors is a different product from Vyleesi, and use outside the approved condition or population, including in men, is outside what the pivotal trials established.
The regulatory picture
Bremelanotide is FDA-approved as Vyleesi for a specific indication (HSDD in premenopausal women), available by prescription. It is not approved for general use, for men, or in an unsupervised, self-directed form. The research-chemical version sold by peptide vendors is a legally and practically different product from the approved drug. It's sold by research chemical vendors strictly for laboratory research, not for human use.
Papa's take
PT-141 is one of the few compounds here I can point to and say the approval is real and the trials are solid, for what they actually studied. The catch is that "actually studied" is narrower than the general sexual-wellness framing suggests, one diagnosed condition, one population, one approved product. That's worth knowing before assuming the approval covers however it's actually being used and sold in research-chem circles.
Sources
Sourcing for research
If you're sourcing PT-141 for laboratory research, purity documentation matters. See my vendor comparisons for how I evaluate third-party certificates of analysis.